Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Changes in metered dose inhaler propellants].

T Chinet1

  • 1Service de Pneumologie, Hôpital Ambroise Paré, Université Paris-V René Descartes, UFR Paris Ouest, Boulogne. thchinet@club-internet.fr

Revue Des Maladies Respiratoires
|April 11, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Nasopharyngeal carriage of SARS-CoV-2 among health personnel with symptoms suggestive of COVID-19 in a University Hospital in the Paris suburbs].

La Revue de medecine interne·2020
Same author

[Screening of occupational exposure to asbestos and silica by job-exposure matrix among patients with lung cancer and mesothelioma].

Revue des maladies respiratoires·2019
Same author

[Outdoor pollution and its effects on lung health in France. Expert document from the Groupe Pathologies pulmonaires professionnelles environnementales et iatrogéniques (PAPPEI) of the Société de pneumologie de langue française (SPLF)].

Revue des maladies respiratoires·2019
Same author

[The effects of inhaled steroids withdrawal in COPD].

Revue des maladies respiratoires·2017
Same author

[The place of inhaled corticosteroids in COPD].

Revue des maladies respiratoires·2016
Same author

[Validation of an evaluation questionnaire for COPD acute exacerbations (Exascore)].

Revue des maladies respiratoires·2015
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Chlorofluorocarbons (CFCs) are being phased out due to ozone depletion. New hydrofluoroalkane (HFA) inhalers are safe but require formulation and design changes, offering performance enhancements.

Area of Science:

  • Environmental Science
  • Pharmaceutical Science
  • Respiratory Medicine

Background:

  • Chlorofluorocarbons (CFCs) pose a significant threat to the stratospheric ozone layer, prompting international agreements for their phase-out.
  • Metered dose inhalers (MDIs) utilizing CFCs for respiratory conditions face a production ban, necessitating the identification of safe and effective alternatives.
  • Hydrofluoroalkanes (HFAs), specifically HFA-134a and HFA-227, have been identified as ozone-safe propellants for MDIs.

Purpose of the Study:

  • To address the challenge of replacing CFCs in MDIs with environmentally safe propellants.
  • To explore the necessary modifications in drug formulation, inhaler design, and manufacturing processes for HFA-based inhalers.
  • To evaluate the potential for performance enhancement in new inhaler designs utilizing HFAs.

Related Experiment Videos

Main Methods:

  • Review of scientific literature on ozone depletion and propellant safety.
  • Analysis of the technical and pharmacological differences between CFC-based and HFA-based inhalers.
  • Monitoring of market introduction and clinical trial outcomes for new HFA inhaler products.

Main Results:

  • Hydrofluoroalkanes (HFAs) are confirmed as safe alternatives with no ozone-damaging potential.
  • Transitioning from CFCs to HFAs necessitates significant changes in inhaler technology and drug formulation.
  • New HFA-based inhalers offer opportunities for improved performance compared to older CFC-based devices.
  • By late 1998, HFA-based inhalers for short-acting beta-agonists and corticosteroids were available in France.

Conclusions:

  • The phase-out of CFCs in MDIs is achievable with the adoption of HFA propellants.
  • The transition to HFA inhalers requires a comprehensive redesign of drug delivery systems.
  • New HFA inhalers represent advancements in respiratory drug delivery, offering potential benefits to patients.